Securities code: 300006 securities abbreviation: Chongqing Lummy Pharmaceutical Co.Ltd(300006) Announcement No.: 2021-090 Chongqing Lummy Pharmaceutical Co.Ltd(300006)
Announcement on the resignation of the chairman of the company
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The board of directors of Chongqing Lummy Pharmaceutical Co.Ltd(300006) (hereinafter referred to as "the company") received a written resignation report submitted by Mr. Peng Weimin, chairman of the company, after the second extraordinary general meeting of shareholders in 2021. Mr. Peng Weimin's original term of office was from June 12, 2020 to June 11, 2023. Now he applies to resign as chairman, director and director of the company due to work adjustment The board of directors has the position of chairman of the strategy committee, and will no longer hold any position in the company after resignation.
In accordance with the company law, Shenzhen Stock Exchange GEM Listing Rules, the articles of association and other relevant provisions, his resignation report shall take effect from the date when it is delivered to the board of directors of the company.
As of the disclosure date of this announcement, Mr. Peng Weimin did not hold any shares of the company, nor did he have any commitments that should be fulfilled but not fulfilled. Mr. Peng Weimin's resignation did not cause the number of members of the board of directors of the company to be lower than the minimum quorum, and would not affect the normal operation of the board of directors of the company.
During his tenure in the company, Mr. Peng Weimin was diligent and conscientious, and made important contributions to the development of the company. The board of directors of the company expressed heartfelt thanks for this!
It is hereby announced.
Chongqing Lummy Pharmaceutical Co.Ltd(300006) board of directors December 30, 2021
